Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ajay K. Singh, M.D., M.B.,B.S.

Title
Institution
Department
Address
Phone
Fax
Other Positions
Title
Institution
Department

Mentoring
Assessing knowledge of diabetes among adolescents in central Sri Lanka and exploring ongoing awareness programs
International, 06/20/06 - 08/20/06

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. M01RR002635 (GOTTLIEB, GARY L) Dec 1, 1984 - Mar 31, 2010
    NIH
    General Clinical Research Center
    Role: Co-Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Mc Causland FR, Singh AK, Claggett BL, Carroll K, Wittes J, McMurray JJV, Perkovic V, Snapinn S, Lopes RD, Solomon SD. Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. Reply. N Engl J Med. 2022 12 29; 387(26):2482-2485. PMID: 36577112.
    Citations:    Fields:    Translation:Humans
  2. Singh AK, Causland FRM, Claggett BL, Wanner C, Wiecek A, Atkins MB, Carroll K, Perkovic V, McMurray JJV, Wittes J, Snapinn S, Blackorby A, Meadowcroft A, Barker T, DiMino T, Mallett S, Cobitz AR, Solomon SD. Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents - post hoc analyses of the ASCEND-ND and ASCEND-D trials. Nephrol Dial Transplant. 2022 Dec 24. PMID: 36565721.
    Citations:    Fields:    
  3. Perkovic V, Blackorby A, Cizman B, Carroll K, Cobitz AR, Davies R, DiMino TL, Jha V, Johansen KL, Lopes RD, Kler L, Macdougall IC, McMurray JJV, Meadowcroft AM, Obrador GT, Solomon S, Taft L, Wanner C, Waikar SS, Wheeler DC, Wiecek A, Singh AK. The ASCEND-ND trial: study design and participant characteristics. Nephrol Dial Transplant. 2022 10 19; 37(11):2157-2170. PMID: 34865143; PMCID: PMC9585467.
    Citations:    Fields:    
  4. Coyne DW, Singh AK, Lopes RD, Bailey CK, DiMino TL, Huang C, Connaire J, Rastogi A, Kim SG, Orias M, Shah S, Patel V, Cobitz AR, Wanner C. Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial. Clin J Am Soc Nephrol. 2022 Sep; 17(9):1325-1336. PMID: 35918106; PMCID: PMC9625096.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  5. Singh AK, Cizman B, Carroll K, McMurray JJV, Perkovic V, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, Wanner C, Wheeler DC, Wiecek A, Stankus N, Strutz F, Blackorby A, Cobitz AR, Meadowcroft AM, Paul G, Ranganathan P, Sedani S, Solomon S. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. JAMA Intern Med. 2022 06 01; 182(6):592-602. PMID: 35377393; PMCID: PMC8981070.
    Citations:    Fields:    Translation:Humans
  6. Singh AK, Blackorby A, Cizman B, Carroll K, Cobitz AR, Davies R, Jha V, Johansen KL, Lopes RD, Kler L, Macdougall IC, McMurray JJV, Meadowcroft AM, Obrador GT, Perkovic V, Solomon S, Wanner C, Waikar SS, Wheeler DC, Wiecek A. Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial. Nephrol Dial Transplant. 2022 04 25; 37(5):960-972. PMID: 33744933; PMCID: PMC9035347.
    Citations: 1     Fields:    Translation:Humans
  7. Johansen KL, Acharya A, Cizman B, Cobitz AR, Correa-Rotter R, Dasgupta I, Kher V, Lopes RD, Matsumoto L, Meadowcroft AM, Merege Vieira Neto O, Okabe M, Rayner B, Silva A, Thomas H, Singh AK. Challenges of Conducting Clinical Trials during the SARS-CoV-2 Pandemic: The ASCEND Global Program Experience. Kidney360. 2022 04 28; 3(4):728-733. PMID: 35721625; PMCID: PMC9136902.
    Citations:    Translation:HumansPHPublic Health
  8. Singh AK, Carroll K, McMurray JJV, Solomon S, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, Wanner C, Wheeler DC, Wiecek A, Blackorby A, Cizman B, Cobitz AR, Davies R, DiMino TL, Kler L, Meadowcroft AM, Taft L, Perkovic V. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2313-2324. PMID: 34739196.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  9. Singh AK, Carroll K, Perkovic V, Solomon S, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, Wanner C, Wheeler DC, Wiecek A, Blackorby A, Cizman B, Cobitz AR, Davies R, Dole J, Kler L, Meadowcroft AM, Zhu X, McMurray JJV. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 12 16; 385(25):2325-2335. PMID: 34739194.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  10. Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, Eckardt KU, McMurray JJV, Weinrauch LA, Liu J, Claggett B, Lewis EF, Pfeffer MA. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2019 05; 21(5):1199-1208. PMID: 30672083.
    Citations: 27     Fields:    Translation:Humans
  11. Mc Causland FR, Claggett B, Burdmann EA, Chertow GM, Cooper ME, Eckardt KU, Ivanovich P, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2019 03; 73(3):309-315. PMID: 30578152; PMCID: PMC6420804.
    Citations: 8     Fields:    Translation:Humans
  12. Mc Causland FR, Claggett B, Pfeffer MA, Burdmann EA, Eckardt KU, Levey AS, McMurray JJV, Remuzzi G, Singh AK, Solomon SD, Toto RD, Parfrey P. Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. Am J Nephrol. 2017; 46(6):488-497. PMID: 29241199; PMCID: PMC5764793.
    Citations: 1     Fields:    Translation:Humans
  13. Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, de Zeeuw D, Eckardt KU, McMurray JJV, Claggett B, Lewis EF, Pfeffer MA. ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. Am J Kidney Dis. 2017 Oct; 70(4):522-531. PMID: 28599901.
    Citations: 4     Fields:    Translation:Humans
  14. Mc Causland FR, Claggett B, Burdmann EA, Eckardt KU, Kewalramani R, Levey AS, McMurray JJ, Parfrey P, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA. C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2016 Dec; 68(6):873-881. PMID: 27646425; PMCID: PMC5123931.
    Citations: 14     Fields:    Translation:Humans
  15. Charytan DM, Lewis EF, Desai AS, Weinrauch LA, Ivanovich P, Toto RD, Claggett B, Liu J, Hartley LH, Finn P, Singh AK, Levey AS, Pfeffer MA, McMurray JJ, Solomon SD. Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2015 Sep; 66(3):429-40. PMID: 25935581; PMCID: PMC4549188.
    Citations: 8     Fields:    Translation:Humans
  16. Surana SP, Pun PH, Keithi-Reddy SR, Spiegel SM, Middleton JP, Singh AK. Sudden cardiac arrest in ESRD patients. Clin Nephrol. 2014 Feb; 81(2):121-31. PMID: 23149247.
    Citations: 2     Fields:    Translation:Humans
  17. Alsuwadia AO, Farag YM, Al Sayyari AA, Mousa DH, Alhejaili FF, Al-Harbi AS, Housawi AA, Mittal BV, Singh AK. Prevalence of vitamin D deficiency in Saudi adults. Saudi Med J. 2013 Aug; 34(8):814-8. PMID: 23974452.
    Citations: 39     Fields:    Translation:Humans
  18. Singh AK. How can erythropoeitin-stimulating agent use be reduced in chronic dialysis patients?: The itsy bitsy anemia problem. Semin Dial. 2013 Sep-Oct; 26(5):531-4. PMID: 23763643.
    Citations: 1     Fields:    Translation:Humans
  19. Singh AK, Farag YM, Mittal BV, Subramanian KK, Reddy SR, Acharya VN, Almeida AF, Channakeshavamurthy A, Ballal HS, P G, Issacs R, Jasuja S, Kirpalani AL, Kher V, Modi GK, Nainan G, Prakash J, Rana DS, Sreedhara R, Sinha DK, V SB, Sunder S, Sharma RK, Seetharam S, Raju TR, Rajapurkar MM. Epidemiology and risk factors of chronic kidney disease in India - results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC Nephrol. 2013 May 28; 14:114. PMID: 23714169.
    Citations: 89     Fields:    Translation:Humans
  20. McCullough PA, Barnhart HX, Inrig JK, Reddan D, Sapp S, Patel UD, Singh AK, Szczech LA, Califf RM. Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. Am J Nephrol. 2013; 37(6):549-58. PMID: 23735819.
    Citations: 48     Fields:    Translation:Humans
  21. Singh AK, Kari JA. Metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens. 2013 Mar; 22(2):198-203. PMID: 23340215.
    Citations: 50     Fields:    Translation:Humans
  22. Sarnak MJ, Tighiouart H, Scott TM, Lou KV, Sorensen EP, Giang LM, Drew DA, Shaffi K, Strom JA, Singh AK, Weiner DE. Frequency of and risk factors for poor cognitive performance in hemodialysis patients. Neurology. 2013 Jan 29; 80(5):471-80. PMID: 23303848; PMCID: PMC3590049.
    Citations: 94     Fields:    Translation:Humans
  23. Farag YM, Kari JA, Singh AK. Chronic kidney disease in the Arab world: a call for action. Nephron Clin Pract. 2012; 121(3-4):c120-3. PMID: 23208083.
    Citations: 13     Fields:    Translation:HumansPHPublic Health
  24. Skali H, Lin J, Pfeffer MA, Chen CY, Cooper ME, McMurray JJ, Nissenson AR, Remuzzi G, Rossert J, Parfrey PS, Scott-Douglas NW, Singh AK, Toto R, Uno H, Ivanovich P. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Am J Kidney Dis. 2013 Feb; 61(2):238-46. PMID: 23159232.
    Citations: 4     Fields:    Translation:Humans
  25. Singh AK. Anaemia: Does the KDIGO guideline move the needle in CKD anaemia? Nat Rev Nephrol. 2012 Nov; 8(11):616-8. PMID: 23007621.
    Citations: 2     Fields:    Translation:Humans
  26. Inrig JK, Barnhart HX, Reddan D, Patel UD, Sapp S, Califf RM, Singh AK, Szczech LA. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am J Kidney Dis. 2012 Sep; 60(3):390-401. PMID: 22537421.
    Citations: 12     Fields:    Translation:Humans
  27. Farag YM, Keithy-Reddy SR, Mittal BV, Bansal V, Fareed J, Singh AK. Modulation of platelet activation in chronic kidney disease patients on erythropoiesis-stimulating agents. Clin Appl Thromb Hemost. 2012 Sep; 18(5):453-61. PMID: 22496088.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  28. Skali H, Parving HH, Parfrey PS, Burdmann EA, Lewis EF, Ivanovich P, Keithi-Reddy SR, McGill JB, McMurray JJ, Singh AK, Solomon SD, Uno H, Pfeffer MA. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation. 2011 Dec 20; 124(25):2903-8. PMID: 22104547.
    Citations: 31     Fields:    Translation:Humans
  29. Singh AK, Singh AK. Is there a deleterious effect of erythropoietin in end-stage renal disease? Kidney Int. 2011 Sep; 80(6):569-71. PMID: 21878954.
    Citations: 1     Fields:    Translation:Humans
  30. Singh AK, Racusen LC. ASN clinicopathologic conference. Clin J Am Soc Nephrol. 2011 Nov; 6(11):2722-8. PMID: 21885795.
    Citations:    Fields:    Translation:Humans
  31. Alsuwaida AO, Farag YM, Al Sayyari AA, Mousa D, Alhejaili F, Al-Harbi A, Housawi A, Mittal BV, Singh AK. Epidemiology of chronic kidney disease in the Kingdom of Saudi Arabia (SEEK-Saudi investigators) - a pilot study. Saudi J Kidney Dis Transpl. 2010 Nov; 21(6):1066-72. PMID: 21060175.
    Citations: 28     Fields:    Translation:HumansPHPublic Health
  32. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010 Sep 16; 363(12):1146-55. PMID: 20843249.
    Citations: 153     Fields:    Translation:Humans
  33. Singh AK. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? Curr Opin Nephrol Hypertens. 2010 Sep; 19(5):420-4. PMID: 20689425.
    Citations: 19     Fields:    Translation:Humans
  34. Singh AK. Message to the FDA on ESAs: REMS is not enough, more studies are needed. Clin J Am Soc Nephrol. 2010 Aug; 5(8):1355-8. PMID: 20688885.
    Citations: 1     Fields:    Translation:Humans
  35. Singh AK, Singh AK. Diabetes, anemia and CKD: Why TREAT? Curr Diab Rep. 2010 Aug; 10(4):291-6. PMID: 20544312.
    Citations: 4     Fields:    Translation:Humans
  36. Patel TV, Singh AK, Singh AK. Anemia in chronic kidney disease: new advances. Heart Fail Clin. 2010 Jul; 6(3):347-57. PMID: 20630409.
    Citations: 6     Fields:    Translation:Humans
  37. Singh AK. Even in nephrology, gurudakshina is important. Kidney Int. 2010 Jul; 78(1):3-5. PMID: 20551921.
    Citations:    Fields:    Translation:Humans
  38. Agarwal AK, Singh AK. Therapy with erythropoiesis-stimulating agents and renal and nonrenal outcomes. Heart Fail Clin. 2010 Jul; 6(3):323-32. PMID: 20630407.
    Citations: 2     Fields:    Translation:Humans
  39. Singh AK. Debate: PRO Position. Should hemoglobin targets for anemic patients with chronic kidney disease be changed? Am J Nephrol. 2010; 31(6):552-6; discussion 563-4. PMID: 20501988.
    Citations:    Fields:    Translation:Humans
  40. Singh AK. ESAs in dialysis patients: are you a hedgehog or a fox? J Am Soc Nephrol. 2010 Apr; 21(4):543-6. PMID: 20357173.
    Citations: 4     Fields:    Translation:Humans
  41. Singh AK. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis. Clin J Am Soc Nephrol. 2010 Apr; 5(4):553-6. PMID: 20203166.
    Citations: 8     Fields:    Translation:HumansCellsPHPublic Health
  42. Singh AK, Singh AK, Nachiappan AC, Verma HA, Uppot RN, Blake MA, Saini S, Boland GW. Postoperative imaging in liver transplantation: what radiologists should know. Radiographics. 2010 Mar; 30(2):339-51. PMID: 20228321.
    Citations: 33     Fields:    Translation:Humans
  43. Singh AK. Should we keep hemoglobin levels as a viable outcome measure? Nephrol News Issues. 2010 Mar; 24(3):15-6, 18. PMID: 20364493.
    Citations: 1     Fields:    Translation:Humans
  44. Ingsathit A, Thakkinstian A, Chaiprasert A, Sangthawan P, Gojaseni P, Kiattisunthorn K, Ongaiyooth L, Vanavanan S, Sirivongs D, Thirakhupt P, Mittal B, Singh AK. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. Nephrol Dial Transplant. 2010 May; 25(5):1567-75. PMID: 20037182.
    Citations: 59     Fields:    Translation:Humans
  45. Singh AK. Does TREAT give the boot to ESAs in the treatment of CKD anemia? J Am Soc Nephrol. 2010 Jan; 21(1):2-6. PMID: 20035034.
    Citations: 20     Fields:    Translation:HumansCells
  46. Mittal BV, Singh AK. Hypertension in the developing world: challenges and opportunities. Am J Kidney Dis. 2010 Mar; 55(3):590-8. PMID: 19962803.
    Citations: 86     Fields:    Translation:Humans
  47. Szczech LA, Barnhart HX, Sapp S, Felker GM, Hernandez A, Reddan D, Califf RM, Inrig JK, Patel UD, Singh AK. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int. 2010 Feb; 77(3):239-46. PMID: 19890274.
    Citations: 24     Fields:    Translation:HumansCTClinical Trials
  48. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 Nov 19; 361(21):2019-32. PMID: 19880844.
    Citations: 641     Fields:    Translation:Humans
  49. Servilla KS, Singh AK, Hunt WC, Harford AM, Miskulin D, Meyer KB, Bedrick EJ, Rohrscheib MR, Tzamaloukas AH, Johnson HK, Zager PG. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization. Am J Kidney Dis. 2009 Sep; 54(3):498-510. PMID: 19628315.
    Citations: 14     Fields:    Translation:Humans
  50. Singh AK. Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: pro. J Am Soc Nephrol. 2009 Jul; 20(7):1436-41. PMID: 19579295.
    Citations: 6     Fields:    Translation:Humans
  51. Fishbane S, Cohen DJ, Coyne DW, Djamali A, Singh AK, Wish JB. Posttransplant anemia: the role of sirolimus. Kidney Int. 2009 Aug; 76(4):376-82. PMID: 19553912.
    Citations: 10     Fields:    Translation:Humans
  52. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill J, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R, Uno H. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis. 2009 Jul; 54(1):59-69. PMID: 19501439.
    Citations: 20     Fields:    Translation:Humans
  53. Alexander MP, Patel TV, Farag YM, Florez A, Rennke HG, Singh AK. Kidney pathological changes in metabolic syndrome: a cross-sectional study. Am J Kidney Dis. 2009 May; 53(5):751-9. PMID: 19339092.
    Citations: 30     Fields:    Translation:Humans
  54. Patel TV, Singh AK. Role of vitamin D in chronic kidney disease. Semin Nephrol. 2009 Mar; 29(2):113-21. PMID: 19371802.
    Citations: 18     Fields:    Translation:HumansAnimals
  55. Patel TV, Singh AK. Kidney disease outcomes quality initiative guidelines for bone and mineral metabolism: emerging questions. Semin Nephrol. 2009 Mar; 29(2):105-12. PMID: 19371801.
    Citations: 3     Fields:    Translation:Humans
  56. Singh A. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence. Semin Dial. 2009 Jan-Feb; 22(1):64-9. PMID: 19175537.
    Citations: 3     Fields:    Translation:Humans
  57. Singh AK. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now? Am J Kidney Dis. 2008 Dec; 52(6 Suppl):S5-13. PMID: 19010260.
    Citations: 10     Fields:    Translation:Humans
  58. Patel TV, Mittal BV, Keithi-Reddy SR, Duffield JS, Singh AK. Endothelial activation markers in anemic non-dialysis chronic kidney disease patients. Nephron Clin Pract. 2008; 110(4):c244-50. PMID: 18974656.
    Citations: 8     Fields:    Translation:Humans
  59. Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, Wang H. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2009 Jan; 53(1):26-32. PMID: 18930568.
    Citations: 72     Fields:    Translation:Humans
  60. Pizzi LT, Bunz TJ, Coyne DW, Goldfarb DS, Singh AK. Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation. Kidney Int. 2008 Dec; 74(12):1588-95. PMID: 19034302.
    Citations: 4     Fields:    Translation:Humans
  61. Patel TV, Singh AK. Does treatment with calcitriol improve survival in predialysis patients with chronic kidney disease? Nat Clin Pract Endocrinol Metab. 2008 Sep; 4(9):484-5. PMID: 18607400.
    Citations: 1     Fields:    
  62. Keithi-Reddy SR, Singh AK. Hemoglobin target in chronic kidney disease: a pediatric perspective. Pediatr Nephrol. 2009 Mar; 24(3):431-4. PMID: 18604563.
    Citations: 3     Fields:    Translation:Humans
  63. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008 Sep; 74(6):791-8. PMID: 18596733.
    Citations: 183     Fields:    Translation:HumansCTClinical Trials
  64. Rocuts AK, Waikar SS, Alexander MP, Rennke HG, Singh AK. Acute phosphate nephropathy. Kidney Int. 2009 May; 75(9):987-91. PMID: 18580858.
    Citations: 7     Fields:    Translation:Humans
  65. Alexander MP, Farag YM, Mittal BV, Rennke HG, Tullius SG, Singh AK. De novo multifocal renal cell carcinoma in the renal allograft. Kidney Int. 2009 Jan; 75(1):111-4. PMID: 18563056.
    Citations: 3     Fields:    Translation:Humans
  66. Fishbane S, Singh AK. Iron deficiency in non-dialysis chronic kidney disease. Kidney Int. 2009 Apr; 75(7):752-4. PMID: 18563050.
    Citations: 2     Fields:    Translation:Humans
  67. Keithi-Reddy SR, Kandasamy S, Singh AK. Pure red cell aplasia due to follow-on epoetin. Kidney Int. 2008 Dec; 74(12):1617-22. PMID: 18547998.
    Citations: 7     Fields:    Translation:Humans
  68. Keithi-Reddy SR, Addabbo F, Patel TV, Mittal BV, Goligorsky MS, Singh AK. Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int. 2008 Sep; 74(6):782-90. PMID: 18547996.
    Citations: 16     Fields:    Translation:HumansCells
  69. Surana SP, Riella LV, Keithi-Reddy SR, Charytan DM, Singh AK. Acute coronary syndrome in ESRD patients. Kidney Int. 2009 Mar; 75(5):558-62. PMID: 18509314.
    Citations: 5     Fields:    Translation:Humans
  70. Singh AK, Milford E, Fishbane S, Keithi-Reddy SR. Managing anemia in dialysis patients: hemoglobin cycling and overshoot. Kidney Int. 2008 Sep; 74(5):679-83. PMID: 18337717.
    Citations: 9     Fields:    Translation:Humans
  71. Kakkar R, Sobieszczyk P, Binkert CA, Faxon DP, Mortele KJ, Singh AK, Singh AK. Prevention of intravenous contrast-induced nephropathy in hospital inpatients. Crit Pathw Cardiol. 2008 Mar; 7(1):1-4. PMID: 18458660.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  72. Kapoian T, O'Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, Kopelman RC, Dahl NV, Coyne DW. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008 Feb; 19(2):372-9. PMID: 18216316.
    Citations: 49     Fields:    Translation:Humans
  73. Singh AK, Fishbane S. The optimal hemoglobin in dialysis patients- a critical review. Semin Dial. 2008 Jan-Feb; 21(1):1-6. PMID: 18251947.
    Citations: 4     Fields:    Translation:Humans
  74. Singh AK. Anemia of chronic kidney disease. Clin J Am Soc Nephrol. 2008 Jan; 3(1):3-6. PMID: 18077779.
    Citations: 4     Fields:    Translation:Humans
  75. Weiner DE, Miskulin DC, Seefeld K, Ladik V, Zager PG, Singh AK, Johnson HK, Meyer KB. Reducing versus discontinuing erythropoietin at high hemoglobin levels. J Am Soc Nephrol. 2007 Dec; 18(12):3184-91. PMID: 17978308.
    Citations: 2     Fields:    Translation:Humans
  76. Singh AK. Does correction of anemia slow the progression of chronic kidney disease? Nat Clin Pract Nephrol. 2007 Dec; 3(12):638-9. PMID: 17940523.
    Citations: 2     Fields:    Translation:HumansAnimals
  77. Patel TV, Robinson K, Singh AK. Is it time to reconsider subcutaneous administration of epoetin? Nephrol News Issues. 2007 Oct; 21(11):57, 59, 63-4 passim. PMID: 17970510.
    Citations: 4     Fields:    Translation:Humans
  78. Singh AK. Anemia of chronic kidney disease: CHOIR and the FDA. Nat Clin Pract Nephrol. 2007 Aug; 3(8):406-7. PMID: 17593919.
    Citations:    Fields:    Translation:Humans
  79. Sharma R, Tewari KN, Bhatnagar A, Mondal A, Mishra AK, Singh AK, Chopra MK, Rawat H, Kashyap R, Tripathi RP. Tc-99m ciprofloxacin scans for detection of tubercular bone infection. Clin Nucl Med. 2007 May; 32(5):367-70. PMID: 17452864.
    Citations: 10     Fields:    Translation:Humans
  80. Singh AK. The FDA black box for EPO: what should nephrologists do? Nephrol News Issues. 2007 May; 21(6):55-6, 58-9. PMID: 17518125.
    Citations: 1     Fields:    Translation:Humans
  81. Provenzano R, Singh AK. Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocr Pract. 2007 May-Jun; 13(3):251-9. PMID: 17599856.
    Citations: 1     Fields:    Translation:Humans
  82. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Anaemia of CKD--the CHOIR study revisited. Nephrol Dial Transplant. 2007 Jul; 22(7):1806-10. PMID: 17420166.
    Citations: 3     Fields:    Translation:Humans
  83. Singh AK, Coyne DW, Shapiro W, Rizkala AR. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int. 2007 Jun; 71(11):1163-71. PMID: 17396118.
    Citations: 21     Fields:    Translation:Humans
  84. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007 Mar; 18(3):975-84. PMID: 17267740.
    Citations: 113     Fields:    Translation:Humans
  85. Singh AK. The target hemoglobin in patients with chronic kidney disease. Nephrol News Issues. 2006 Dec; 20(13):29-30. PMID: 17168056.
    Citations: 1     Fields:    Translation:Humans
  86. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16; 355(20):2085-98. PMID: 17108343.
    Citations: 729     Fields:    Translation:Humans
  87. Brenner L, Singh AK, Singh AK, Campbell D, Frei F, Winkelmayer WC. Associations between demographic factors and provider structures on cost and length of stay for hemodialysis patients with vascular access failure. Clin J Am Soc Nephrol. 2006 May; 1(3):455-61. PMID: 17699245.
    Citations: 4     Fields:    Translation:Humans
  88. Pendse S, Singh AK, Singh AK. Complications of chronic kidney disease: anemia, mineral metabolism, and cardiovascular disease. Med Clin North Am. 2005 May; 89(3):549-61. PMID: 15755467.
    Citations: 6     Fields:    Translation:Humans
  89. Singh AK, Hertello P. The benefits of IV iron therapy in treating anemia in patients with renal disease and comorbid cardiovascular disease. Nephrol Nurs J. 2005 Mar-Apr; 32(2):199-206; quiz 207-8. PMID: 15889804.
    Citations:    Fields:    Translation:Humans
  90. Mix TC, Brenner RM, Cooper ME, de Zeeuw D, Ivanovich P, Levey AS, McGill JB, McMurray JJ, Parfrey PS, Parving HH, Pereira BJ, Remuzzi G, Singh AK, Solomon SD, Stehman-Breen C, Toto RD, Pfeffer MA. Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J. 2005 Mar; 149(3):408-13. PMID: 15864229.
    Citations: 28     Fields:    Translation:Humans
  91. Mittal B, Rennke H, Singh AK. The role of kidney biopsy in the management of lupus nephritis. Curr Opin Nephrol Hypertens. 2005 Jan; 14(1):1-8. PMID: 15586009.
    Citations: 8     Fields:    Translation:Humans
  92. Pfeffer MA, Solomon SD, Singh AK, Ivanovich P, McMurray JJ. Uncertainty in the treatment of anemia in chronic kidney disease. Rev Cardiovasc Med. 2005; 6 Suppl 3:S35-41. PMID: 16340937.
    Citations:    Fields:    Translation:Humans
  93. Mittal B, Hurwitz S, Rennke H, Singh AK. New subcategories of class IV lupus nephritis: are there clinical, histologic, and outcome differences? Am J Kidney Dis. 2004 Dec; 44(6):1050-9. PMID: 15558526.
    Citations: 22     Fields:    Translation:Humans
  94. Pendse S, Ginsburg E, Singh AK. Strategies for preservation of ovarian and testicular function after immunosuppression. Am J Kidney Dis. 2004 May; 43(5):772-81. PMID: 15112167.
    Citations: 10     Fields:    Translation:HumansCells
  95. Singh AK, Colvin RB. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 36-2003. A 68-year-old woman with impaired renal function. N Engl J Med. 2003 Nov 20; 349(21):2055-63. PMID: 14627791.
    Citations: 6     Fields:    Translation:Humans
  96. Lin J, Knight EL, Hogan ML, Singh AK. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol. 2003 Oct; 14(10):2573-80. PMID: 14514734.
    Citations: 88     Fields:    Translation:HumansCTClinical Trials
  97. Kewalramani R, Singh AK. Immunopathogenesis of lupus and lupus nephritis: recent insights. Curr Opin Nephrol Hypertens. 2002 May; 11(3):273-7. PMID: 11981256.
    Citations: 4     Fields:    Translation:HumansCells
  98. Singh AK. Immunopathogenesis of the antiphospholipid antibody syndrome: an update. Curr Opin Nephrol Hypertens. 2001 May; 10(3):355-8. PMID: 11342797.
    Citations:    Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Singh's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (306)
Explore
_
Co-Authors (28)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.